ERBITUX Drug Profile
✉ Email this page to a colleague
Summary for Tradename: ERBITUX
| High Confidence Patents: | 1 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for ERBITUX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ERBITUX |
Recent Clinical Trials for ERBITUX
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 1/Phase 2 |
| BioMed Valley Discoveries, Inc | Phase 1 |
| Jonathan Riess | Phase 1 |
Recent Litigation for ERBITUX
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd. | 2023-10-20 |
| Janssen Biotech, Inc. v. Amgen Inc. | 2022-11-29 |
| Ravgen, Inc. v. Quest Diagnostics Incorporated | 2021-11-17 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Illumina, Inc. et al. | 2021-07-20 |
| Laboratory Corporation of America Holdings et al. | 2021-05-28 |
| Quest Diagnostics Incorporated | 2021-04-15 |
Pharmacology for ERBITUX
| Mechanism of Action | HER1 Antagonists |
| Established Pharmacologic Class | Epidermal Growth Factor Receptor Antagonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for ERBITUX Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for ERBITUX Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 6,217,866 | 2018-04-17 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for ERBITUX Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 10,004,694 | 2032-09-12 | Patent claims search |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 10,011,659 | 2034-09-08 | Patent claims search |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 10,016,338 | 2033-03-11 | Patent claims search |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 10,016,365 | 2039-02-26 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for ERBITUX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Germany | 122008000028 | ⤷ Subscribe |
| Germany | 122008000030 | ⤷ Subscribe |
| Germany | 122008000027 | ⤷ Subscribe |
| Germany | 122004000041 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ERBITUX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122008000030 | Germany | ⤷ Subscribe | PRODUCT NAME: PANITUMUMAB MIT WENIGSTENS EINEM WIRKSTOFF AUSGEWAEHLT AUS IRINOTECAN, CISPLATIN, 5-FLUOROURACIL, GEMCITABIN, PACLITAXEL UND CARBOPLATIN; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203 |
| 122004000040 | Germany | ⤷ Subscribe | PRODUCT NAME: CETUXIMAB IN KOMBINATION MIT IRINOTECAN; REGISTRATION NO/DATE: EU/1/04/281/001 20040629 |
| 122008000027 | Germany | ⤷ Subscribe | PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203 |
| 122004000041 | Germany | ⤷ Subscribe | PRODUCT NAME: CETUXIMAB; REGISTRATION NO/DATE: EU/1/04/281/001 20040629 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
